• 1
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
  • 2
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123.
  • 3
    Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11: 835-844.
  • 4
    Pucciarelli S, Friso ML, Toppan P, et al. Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results. Ann Surg Oncol. 2000; 7: 38-44.
  • 5
    Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429: 464-468.
  • 6
    Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003; 3: 912-920.
  • 7
    International HapMap Consortium. The International HapMap Project. Nature. 2003; 426: 789-796.
  • 8
    Frazer KA, Ballinger DG, Consortium IH, Cox DR, Hinds DA, Stewart J. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449: 851-861.
  • 9
    Booton R, Ward T, Heighway J, et al. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer. 2006; 106: 2421-2427.
  • 10
    Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemoradiotherapy. Pharmacogenomics J. 2011; 11: 214-226.
  • 11
    Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010; 10: 54-61.
  • 12
    Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz H. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001; 61: 8654-8658.
  • 13
    Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006; 24: 4333-4339.
  • 14
    Wu X, Gu J, Wu T, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006; 24: 3789-3798.
  • 15
    Garcia-Aguilar J, Chen Z, Smith DD, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011; 254: 486-493.
  • 16
    Boige V, Mendiboure J, Pignon J, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010; 28: 2556-2564.
  • 17
    Chang-Claude J, Ambrosone CB, Lilla C, et al. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer. 2009; 100: 1680-1686.
  • 18
    Chang-Claude J, Popanda O, Tan X, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res. 2005; 11: 4802-4809.
  • 19
    Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res. 2006; 12: 2545-2554.
  • 20
    Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007; 13: 2876-2881.
  • 21
    Keam B, Im S, Han S, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker [serial online]. BMC Cancer. 2008; 8: 148.
  • 22
    Schirmer MA, Nadine Mergler CP, Rave-Frank M, et al. Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. Int J Radiat Oncol Biol Phys. 2012; 83: 149-157.
  • 23
    Thomas F, Motsinger-Reif AA, Hoskins JM, et al. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer. 2011; 105: 1654-1662.
  • 24
    Garcia-Aguilar J, Smith DD, Avila K, Chen Z, Li W. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a prospective trial. Ann Surg. 2011; 254: 97-102.
  • 25
    Biros E, Kalina I, Biros I, et al. Polymorphism of the p53 gene within the codon 72 in lung cancer patients. Neoplasma. 2001; 48: 407-411.
  • 26
    Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW. Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J. 2007; 26: 541-546.
  • 27
    Monaco R, Rosal R, Dolan MA, Pincus MR, Freyer G, Brandt-Rauf PW. Conformational effects of a common codon 751 polymorphism on the C-terminal domain of the xeroderma pigmentosum D protein [serial online]. J Carcinog. 2009; 8: 12.
  • 28
    Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001; 61: 1354-1357.
  • 29
    Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000; 21: 551-555.
  • 30
    Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004; 15: 1194-1203.
  • 31
    Shen H, Solari A, Wang X, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004; 11: 1115-1120.
  • 32
    Wu X, Zhao H, Amos CI, et al. P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002; 94: 681-690.
  • 33
    Pim D, Banks L. P53 polymorphic variants at codon 72 exert different effects on cell cycle progression, Int J Cancer. 2004; 108: 196-199.
  • 34
    Bonafe M, Salvioli S, Barbi C, et al. P53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun. 2002; 299: 539-541.
  • 35
    Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 2005; 26: 1770-1773.
  • 36
    Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33: 357-365.
  • 37
    Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet. 2000; 25: 47-54.